The other biomarkers: What should rheumatologists know?;Los otros biomarcadores. i Qué debe saber el reumatólogo?

Seminarios de la Fundacion Espanola de Reumatologia

Volumn 12, Issue 3, 2011, Pages 67-72

  Silva Fernandez, Lucia ^a   Barbadillo Mateos, Carmen ^a   Fernandez Castro, Monica ^a   Oton Sanchez, Teresa ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Natriuretic peptide; Procalcitonin; Troponin

Indexed keywords

BIOLOGICAL MARKER; NATRIURETIC PEPTIDE RECEPTOR A; PROCALCITONIN; TROPONIN;

AUTOIMMUNE DISEASE; BLOOD; BODY FLUID; FOLLOW UP; HUMAN; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PROGNOSIS; RHEUMATOLOGY; SHORT SURVEY;

EID: 79961115180     PISSN: 15773566     EISSN: 19883099     Source Type: Journal    
DOI: 10.1016/j.semreu.2011.02.002     Document Type: Short Survey

References (78)

1. Aruoma O.I., Bahorun T. The future of biomarkers. Toxicology. 2010, 278:161-164.
2. Jones R. Biomarkers: casting the net wide. Nature. 2010, 466:S11-12.
3. Ghasemzadeh N., Wilhelmsen T.W., Nyberg F., Hjerten S. Precautions to improve the accuracy of quantitative determinations of biomarkers in clinical diagnostics. Electrophoresis. 2010, 31:2722-2729.
4. Hendrick S. Measuring chemicals in humans: state biomonitoring policies. NCSL Legisbrief. 2010, 18:1-2.
5. Holliday E.G., Scott R.J., Attia J. Evidence-based medicine in the era of biomarkers: teaching a new dog old tricks?. Clin Pharmacol Ther. 2010, 88:740-742.
6. Russwurm S., Oberhoffer M., Zipfel P.F., Reinhart K. Procalcitonin -a novel biochemical marker for the mediator-directed therapy of sepsis. Mol Med Today. 1999, 5:286-287.
7. Nishikura T. Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med. 1999, 25:1031.
8. Assicot M., Gendrel D., Carsin H., Raymond J., Guilbaud J., Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993, 341:515-518.
9. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002, 323:17-29.
10. Preas H.L., Nylen E.S., Snider R.H., Becker K.L., White J.C., Agosti J.M., et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001, 184:373-376.
11. Gendrel D., Raymond J., Coste J., Moulin F., Lorrot M., Guerin S., et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. 1999, 18:875-881.
12. Muller B., Peri G., Doni A., Perruchoud A.P., Landmann R., Pasqualini F., et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol. 2002, 72:643-649.
13. Karzai W., Oberhoffer M., Meier-Hellmann A., Reinhart K. Procalcitonin -a new indicator of the systemic response to severe infections. Infection. 1997, 25:329-334.
14. Gendrel D., Bohuon C. Procalcitonin, a marker of bacterial infection. Infection. 1997, 25:133-134.
15. Muller B., Becker K.L., Schachinger H., Rickenbacher P.R., Huber P.R., Zimmerli W., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000, 28:977-983.
16. Nylen E.S., Snider R.H., Thompson K.A., Rohatgi P., Becker K.L. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 1996, 312:12-18.
17. Schwarz S., Bertram M., Schwab S., Andrassy K., Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med. 2000, 28:1828-1832.
18. Marc E., Menager C., Moulin F., Stos B., Chalumeau M., Guerin S., et al. Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak. Arch Pediatr. 2002, 9:358-364.
19. Rau B.M., Kemppainen E.A., Gumbs A.A., Buchler M.W., Wegscheider K., Bassi C., et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. Ann Surg. 2007, 245:745-754.
20. Kylanpaa-Back M.L., Takala A., Kemppainen E., Puolakkainen P., Haapiainen R., Repo H. Procalcitonin strip test in the early detection of severe acute pancreatitis. Br J Surg. 2001, 88:222-227.
21. Ammori B.J., Becker K.L., Kite P., Snider R.H., Nylen E.S., White J.C., et al. Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. Pancreas. 2003, 27:239-243.
22. Laifer G., Wasner M., Sendi P., Graber P., Gratzl O., Huber P., et al. Dynamics of serum procalcitonin in patients after major neurosurgery. Clin Microbiol Infect. 2005, 11:679-681.
23. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004, 39:206-217.
24. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G.Y. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006, 34:1996-2003.
25. Eberhard O.K., Haubitz M., Brunkhorst F.M., Kliem V., Koch K.M., Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997, 40:1250-1256.
26. Tamaki K., Kogata Y., Sugiyama D., Nakazawa T., Hatachi S., Kageyama G., et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol. 2008, 35:114-119.
27. Shin K.C., Lee Y.J., Kang S.W., Baek H.J., Lee E.B., Kim H.A., et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis. 2001, 60:988-999.
28. Lanoix JP, Bourgeois AM, Schmit J, Desblache J, Salle V, Smail A, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus. 2011;20:125-30..
29. Quintana G., Medina Y.F., Rojas C., Fernandez A., Restrepo J.F., Rondon F., et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol. 2008, 14:138-142.
30. Schwenger V., Sis J., Breitbart A., Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998, 26:274-276.
31. Daniels L.B., Maisel A.S. Natriuretic peptides. J Am Coll Cardiol. 2007, 50:2357-2368.
32. Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Biology of the natriuretic peptides. Am J Cardiol. 2008, 101:3-8.
33. Maisel A., Mueller C., Adams K., Anker S.D., Aspromonte N., Cleland J.G., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008, 10:824-839.
34. Souza R., Jardim C., Julio Cesar Fernandes C., Silveira Lapa M., Rabelo R., Humbert M. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med. 2007, 101:69-75.
35. Leuchte H.H., Holzapfel M., Baumgartner R.A., Neurohr C., Vogeser M., Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest. 2005, 128:2368-2374.
36. Andreassen A.K., Wergeland R., Simonsen S., Geiran O., Guevara C., Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006, 98:525-529.
37. Allanore Y., Borderie D., Meune C., Cabanes L., Weber S., Ekindjian O.G., et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum. 2003, 48:3503-3508.
38. Simeoni S., Lippi G., Puccetti A., Montagnana M., Tinazzi E., Prati D., et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int. 2008, 28:657-660.
39. Dimitroulas T., Giannakoulas G., Karvounis H., Koliakos G., Sfetsios T., Dimitroula H., et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol. 2008, 27:655-658.
40. Williams M.H., Handler C.E., Akram R., Smith C.J., Das C., Smee J., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006, 27:1485-1494.
41. Karadag O., Calguneri M., Yavuz B., Atalar E., Akdogan A., Kalyoncu U., et al. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?. Clin Rheumatol. 2007, 26:1701-1704.
42. Chung C.P., Solus J.F., Oeser A., Avalos I., Kurnik D., Raggi P., et al. N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: relationship with inflammation, augmentation index, and coronary calcification. J Rheumatol. 2008, 35:1314-1319.
43. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832.
44. Harney S.M., Timperley J., Daly C., Harin A., James T., Brown M.A., et al. Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2006, 65:136.
45. Solus J., Chung C.P., Oeser A., Avalos I., Gebretsadik T., Shintani A., et al. Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum. 2008, 58:2662-2669.
46. Armstrong D.J., Gardiner P.V., O'Kane M.J. Rheumatoid arthritis patients with active disease and no history of cardiac pathology have higher Brain Natriuretic Peptide (BNP) levels than patients with inactive disease or healthy control subjects. Ulster Med J. 2010, 79:82-84.
47. Provan S.A., Angel K., Odegard S., Mowinckel P., Atar D., Kvien T.K. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther. 2008, 10:R70.
48. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., Jacobsen S.J., Roger V.L., et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis. 2007, 66:76-80.
49. Provan S., Angel K., Semb A.G., Atar D., Kvien T.K. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis. 2010, 69:1946-1950.
50. Peters M.J., Welsh P., McInnes I.B., Wolbink G., Dijkmans B.A., Sattar N., et al. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis. 2010, 69:1281-1285.
51. Daubert M.A., Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag. 2010, 6:691-699.
52. Missov E.D., De Marco T. Clinical insights on the use of highly sensitive cardiac troponin assays. Clin Chim Acta. 1999, 284:175-185.
53. Thygesen K., Alpert J.S., White H.D., Jaffe A.S., Apple F.S., Galvani M., et al. Universal definition of myocardial infarction. Circulation. 2007, 116:2634-2653.
54. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007, 116:e148-e304.
55. Morrow D.A., Cannon C.P., Jesse R.L., Newby L.K., Ravkilde J., Storrow A.B., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007, 115:e356-e375.
56. Jaffe A.S., Babuin L., Apple F.S. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006, 48:1-11.
57. Adams J.E., Abendschein D.R., Jaffe A.S. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?. Circulation 1993, 88:750-763.
58. D'Costa M., Fleming E., Patterson M.C. Cardiac troponin I for the diagnosis of acute myocardial infarction in the emergency department. Am J Clin Pathol. 1997, 108:550-555.
59. Wu A.H., Feng Y.J., Contois J.H., Pervaiz S. Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. Ann Clin Lab Sci. 1996, 26:291-300.
60. Martins J.T., Li D.J., Baskin L.B., Jialal I., Keffer J.H. Comparison of cardiac troponin I and lactate dehydrogenase isoenzymes for the late diagnosis of myocardial injury. Am J Clin Pathol. 1996, 106:705-708.
61. Pervaiz S., Anderson F.P., Lohmann T.P., Lawson C.J., Feng Y.J., Waskiewicz D., et al. Comparative analysis of cardiac troponin I and creatine kinase-MB as markers of acute myocardial infarction. Clin Cardiol. 1997, 20:269-271.
62. Apple F.S., Falahati A., Paulsen P.R., Miller E.A., Sharkey S.W. Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I. Clin Chem. 1997, 43:2047-2051.
63. Khan I.A., Tun A., Wattanasauwan N., Win M.T., Hla T.A., Hussain A., et al. Elevation of serum cardiac troponin I in noncardiac and cardiac diseases other than acute coronary syndromes. Am J Emerg Med. 1999, 17:225-229.
64. Simpson J.A., Labugger R., Collier C., Brison R.J., Iscoe S., Van Eyk J.E. Fast and slow skeletal troponin I in serum from patients with various skeletal muscle disorders: a pilot study. Clin Chem. 2005, 51:966-972.
65. Montagnana M., Lippi G., Volpe A., Salvagno G.L., Biasi D., Caramaschi P., et al. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem. 2006, 39:913-917.
66. Krahn J., Parry D.M., Leroux M., Dalton J. High percentage of false positive cardiac troponin I results in patients with rheumatoid factor. Clin Biochem. 1999, 32:477-480.
67. Fitzmaurice T.F., Brown C., Rifai N., Wu A.H., Yeo K.T. False increase of cardiac troponin I with heterophilic antibodies. Clin Chem. 1998, 44:2212-2214.
68. Onuska K.D., Hill S.A. Effect of rheumatoid factor on cardiac troponin I measurement using two commercial measurement systems. Clin Chem. 2000, 46:307-308.
69. Dasgupta A., Banerjee S.K., Datta P. False-positive troponin I in the MEIA due to the presence of rheumatoid factors in serum. Elimination of this interference by using a polyclonal antisera against rheumatoid factors. Am J Clin Pathol. 1999, 112:753-756.
70. Katwa G., Komatireddy G., Walker S.E. False positive elevation of cardiac troponin I in seropositive rheumatoid arthritis. J Rheumatol. 2001, 28:2750-2751.
71. Fleming S.M., O'Byrne L., Finn J., Grimes H., Daly K.M. False-positive cardiac troponin I in a routine clinical population. Am J Cardiol. 2002, 89:1212-1215.
72. Al-Awadhi A.M., Olusi S., Hasan E.A., Abdullah A. Serum concentrations of cardiac troponin-I in patients with rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome and Graves' disease. Singapore Med J. 2007, 48:847-849.
73. Kenny P.R., Finger D.R. Falsely elevated cardiac troponin-I in patients with seropositive rheumatoid arthritis. J Rheumatol. 2005, 32:1258-1261.
74. Bas S., Genevay S., Mensi N. False positive elevation of cardiac troponin I in seropositive rheumatoid arthritis. J Rheumatol. 2002, 29:2665.
75. Aggarwal R., Lebiedz-Odrobina D., Sinha A., Manadan A., Case J.P. Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. J Rheumatol. 2009, 36:2711-2714.
76. Fisher C., Agrawal S., Wong W.M., Fahie-Wilson M., Dasgupta B. Clinical observations on the significance of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology practice. Clin Rheumatol. 2010, 29:1107-1111.
77. Erlacher P., Lercher A., Falkensammer J., Nassonov E.L., Samsonov M.I., Shtutman V.Z., et al. Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. Clin Chim Acta. 2001, 306:27-33.
78. Kiely P.D., Bruckner F.E., Nisbet J.A., Daghir A. Serum skeletal troponin I in inflammatory muscle disease: relation to creatine kinase, CKMB and cardiac troponin I. Ann Rheum Dis. 2000, 59:750-751.